# A Pharmacokinetic Dose Proportionality Study of Canagliflozin in Healthy Volunteers

> **NCT01340677** · PHASE1 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 24 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Canagliflozin, 50 mg
- **DRUG:** Canagliflozin, 300 mg
- **DRUG:** Canagliflozin, 100 mg

## Key facts

- **NCT ID:** NCT01340677
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2011-08
- **Final completion:** 2011-08
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2012-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01340677

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01340677, "A Pharmacokinetic Dose Proportionality Study of Canagliflozin in Healthy Volunteers". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01340677. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*